Fig. 12.
Effect of cytochalasin B, alrestatin, aminoguanidine, and NADPH oxidase inhibition on PKC-βII expression. A: PKC-β mRNA expression and PKC-βII protein levels (means ± SE; n = 5). B: PKC-β mRNA and PKC-βII protein levels (means ± SE; n = 3). *P < 0.05 vs. vehicle in the presence of HG; †P < 0.05 vs. the corresponding treatment in the presence of NG.